ACADIA PHARMACEUTICALS INC. Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value
ACADIA PHARMACEUTICALS INC. (ACAD) had Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value of $0 as of 2024-12-31, per its 10-K filed 2025-02-27.
Financial Statements › Notes › Fair Value Disclosures › Fair Value, Assets and Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation
us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue · last filed 2025-02-27
- 2024-12-31: Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value $0.00.
- 2024-09-30: Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value $0.00.
- 2024-06-30: Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value $0.00.
- 2024-03-31: Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value $200.00K.
| Period end | Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value |
|---|---|
| 2024-12-31 | $0.00 10-K · filed 2025-02-27 |
| 2024-09-30 | $0.00 10-Q · filed 2024-11-07 |
| 2024-06-30 | $0.00 10-Q · filed 2024-08-07 |
| 2024-03-31 | $200.00K 10-Q · filed 2024-05-09 |
| 2023-12-31 | $4.51M 10-K · filed 2025-02-27 |
| 2023-09-30 | $1.11M 10-Q · filed 2023-11-03 |
| 2023-06-30 | $2.13M 10-Q · filed 2023-08-03 |
| 2023-03-31 | $1.25M 10-Q · filed 2023-05-08 |
| 2022-12-31 | $898.00K 10-K · filed 2024-02-28 |
| 2022-09-30 | $989.00K 10-Q · filed 2022-11-03 |
| 2022-06-30 | $694.00K 10-Q · filed 2022-08-09 |
| 2022-03-31 | $1.50M 10-Q · filed 2022-05-05 |
| 2021-12-31 | $603.00K 10-K · filed 2023-02-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| AbCellera Biologics Inc. (ABCL) | $3.879B | -14.59 | |
| Xenon Pharmaceuticals Inc. (XENE) | $3.684B | -14.27 | |
| Organon & Co. (OGN) | United States | $3.603B | 17.03 |
| IDEAYA Biosciences, Inc. (IDYA) | United States | $3.540B | -20.52 |
| Tango Therapeutics, Inc. (TNGX) | United States | $4.154B | -42.53 |
| Indivior Pharmaceuticals, Inc. (INDV) | $4.250B | 14.09 | |
| Amylyx Pharmaceuticals, Inc. (AMLX) | United States | $3.361B | -13.15 |
| Viking Therapeutics, Inc. (VKTX) | United States | $4.287B | -8.51 |
| Enliven Therapeutics, Inc. (ELVN) | United States | $3.307B | -35.07 |
| Arcutis Biotherapeutics, Inc. (ARQT) | United States | $3.303B | 115.47 |